Cognetivity Neurosciences Ltd.
CGNSF
$0.0023
-$0.0077-77.00%
| 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -56.34% | -68.22% | -55.09% | -47.44% | -19.26% |
| Gross Profit | 59.52% | 69.59% | 56.15% | 48.49% | 19.26% |
| SG&A Expenses | -54.56% | -68.37% | -63.93% | -59.77% | 31.47% |
| Depreciation & Amortization | -8.88% | -11.47% | -9.13% | -3.08% | 35.44% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -58.87% | -65.17% | -57.59% | -52.90% | 11.74% |
| Operating Income | 59.81% | 65.63% | 57.94% | 53.23% | -11.74% |
| Income Before Tax | 18.49% | 44.65% | 44.59% | 45.74% | -10.61% |
| Income Tax Expenses | -- | -- | -- | -- | -183.19% |
| Earnings from Continuing Operations | 18.39% | 44.65% | 44.59% | 45.74% | -10.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.39% | 44.65% | 44.59% | 45.74% | -10.30% |
| EBIT | 59.81% | 65.63% | 57.94% | 53.23% | -11.74% |
| EBITDA | 59.95% | 65.74% | 58.03% | 53.32% | -11.69% |
| EPS Basic | 25.55% | 50.53% | 50.67% | 50.07% | 3.20% |
| Normalized Basic EPS | 23.92% | 49.95% | 51.08% | 50.23% | 3.11% |
| EPS Diluted | 25.55% | 50.53% | 50.67% | 50.07% | 3.20% |
| Normalized Diluted EPS | 23.92% | 49.95% | 51.08% | 50.23% | 3.11% |
| Average Basic Shares Outstanding | 10.97% | 11.00% | 15.72% | 12.22% | 16.64% |
| Average Diluted Shares Outstanding | 10.97% | 11.00% | 15.72% | 12.22% | 16.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
